July 10, 2025

HHS Scraps Preventive Care Panel Meeting

HHS unexpectedly canceled a meeting of the U.S. Preventive Services Task Force, prompting fears it may be dismantled following similar moves by Secretary Robert F. Kennedy Jr. at other federal health agencies.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Refractory Esophageal Varices: Strategies Compared

A new review outlines updated strategies for managing refractory esophageal varices, comparing international guidelines and highlighting minimally invasive options such as embolization and stenting when endoscopic methods fail.

Conexiant

June 23, 2025

Is Smoking a Surgical Risk Multiplier?

A study of nearly 700 patients found that smokers undergoing surgery for esophageal cancer experienced significantly more complications, including higher rates of pneumonia and respiratory distress, than nonsmokers—though smoking did not independently impact long-term survival.

Conexiant

June 17, 2025

Anal Cancer Screening Cost-Effective at 35

A large modeling study evaluated the cost-effectiveness, benefits, and harms of anal cancer screening strategies for men who have sex with men living with HIV.

Conexiant

May 02, 2024

SUC2C Grant Could Facilitate Development of Novel Therapies in Gastroesophageal Cancer

A new collaboration between Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center to enhance gastroesophageal cancer care in patients who do not respond to standard treatment has received a 3-year grant from Stand Up To Cancer (SU2C).

Conexiant

April 26, 2024

FDA Grants Orphan Drug Designation to Novel Pancreatic Cancer Drug Candidate

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the novel drug candidate FL118 for the treatment of patients with pancreatic cancer.

Conexiant

April 26, 2024

Irinotecan Liposome Approved by FDA for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma.

Conexiant

October 18, 2024

FDA Approves New Gastric Cancer Therapy

The FDA has approved Vyloy, a monoclonal antibody, for the treatment of gastric cancer in combination with chemotherapy, marking a significant step in targeted therapy for this disease.

Reuters